Small vaccine bottles on a conveyor belt
Pfizer and Moderna COVID-19 Omicron Boosters Get OK from the FDA
The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.
Pfizer and Moderna COVID-19 Omicron Boosters Get OK from the FDA
Pfizer and Moderna COVID-19 Omicron Boosters Get OK from the FDA

The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.

The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.

emergency use authorization (EUA)
Several silver foil pill packs with white pills
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19
Jef Akst | Dec 23, 2021
Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.
building sign
Johnson & Johnson Vaccine Garners First Full Approval
Chloe Tenn | Nov 24, 2021
Health Canada has given the single COVID-19 shot the official greenlight for use in people 18 and older.
convalescent plasma covid-19 coronavirus pandemic sars-cov-2 antibodies clinical trial NIH emergency use authorization
NIH Halts Outpatient COVID-19 Convalescent Plasma Trial
Marcus A. Banks | Mar 4, 2021
The decision adds to evidence that the benefits of plasma infusions from COVID-19 survivors may be limited, but advocates say the case isn’t closed.
COVID-19, SARS-CoV-2, Johnson & Johnson, Pfizer, Moderna, vaccine, vaccination, variant, FDA
US Authorizes a Third COVID-19 Vaccine
Asher Jones | Mar 1, 2021
Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.
Opinion: Emergency Use Authorizations Are a Threat to Science 
Kevin J. Tracey and Christina Brennan | Dec 1, 2020
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.